A new retrospective study shows a high cure rate exceeding 97 percent among older patients (mean age: 82.5 years) being treated for basal cell carcinoma (BCC) and squamous cell carcinomas (SCC) on their lower extremities with SRT-100^TM Superficial Radiation Therapy from Sensus Healthcare.

The article, “Superficial Radiation Therapy: A Viable Nonsurgical Option for Treating Basal and Squamous Cell Carcinoma of the Lower Extremities” appears in the February issue of the Journal of Drugs in Dermatology.

“When treating NMSC of the lower extremities, it is critically important to examine every treatment option that doesn’t inflict more pain or add potential complications as many of these patients are elderly and present with numerous comorbidities,” said William Roth, MD, lead author of the study and Voluntary Clinical Professor at The University of Miami School of Medicine, Department of Dermatology. “The results of this study highlight SRT as a highly effective treatment option for eliminating basal and squamous cell carcinoma lesions on lower extremities.”  

SRT effectively treats basal and squamous cell carcinomas without cutting, bleeding or stitching. There is no need for anesthesia and no need for reconstructive plastic surgery. Sensus’ SRT-100^TM is cleared by the FDA for the treatment of non-melanoma skin cancer and keloids.

“The power of this technology lies in our ability to deliver a precise, calibrated dose of X-ray radiation that penetrates only five millimeters below the skin’s surface,” adds Isabelle Raymond, PhD, Vice President, Clinical Development, Sensus Healthcare. “Dr. Roth’s study demonstrates that basal cell carcinoma and squamous cell carcinoma of the lower extremities can be treated safely and very successfully with superficial radiation therapy, and that it is a viable nonsurgical treatment option for patients who do not want surgery.”